诱导多能干细胞在心血管药物研发中的应用。
Induced pluripotent stem cells in cardiovascular drug discovery.
机构信息
Muscle Development and Regeneration Program, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Rd, La Jolla, CA 92037, USA.
出版信息
Circ Res. 2013 Feb 1;112(3):534-48. doi: 10.1161/CIRCRESAHA.111.250266.
Abstract
The unexpected discovery that somatic cells can be reprogrammed to a pluripotent state yielding induced pluripotent stem cells has made it possible to produce cardiovascular cells exhibiting inherited traits and disorders. Use of these cells in high throughput analyses should broaden our insight into fundamental disease mechanisms and provide many benefits for patients, including new therapeutics and individually tailored therapies. Here we review recent progress in generating induced pluripotent stem cell-based models of cardiovascular disease and their multiple applications in drug development.
摘要
体细胞可被重编程为多能状态，产生诱导多能干细胞，这一意外发现使得产生具有遗传特征和疾病的心血管细胞成为可能。这些细胞在高通量分析中的应用应该拓宽我们对基本疾病机制的认识，并为患者带来许多好处，包括新的治疗方法和个体化治疗。在这里，我们回顾了最近在生成基于诱导多能干细胞的心血管疾病模型方面的进展及其在药物开发中的多种应用。
相似文献
1
Induced pluripotent stem cells in cardiovascular drug discovery.诱导多能干细胞在心血管药物研发中的应用。
Circ Res. 2013 Feb 1;112(3):534-48. doi: 10.1161/CIRCRESAHA.111.250266.
2
Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production.人诱导多能干细胞在心血管研究中的应用：心脏分化的当前方法、成熟策略和可扩展生产。
Cardiovasc Res. 2022 Jan 7;118(1):20-36. doi: 10.1093/cvr/cvab115.
3
A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.人多能干细胞衍生心肌细胞在高通量药物发现、心脏毒性筛选和出版标准中的应用综述。
J Cardiovasc Transl Res. 2013 Feb;6(1):22-30. doi: 10.1007/s12265-012-9423-2. Epub 2012 Nov 15.
4
The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.诱导多能干细胞在心脏疾病建模和药物测试中的应用。
J Cardiovasc Transl Res. 2018 Oct;11(5):366-374. doi: 10.1007/s12265-018-9811-3. Epub 2018 May 29.
5
High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.用于药物开发的诱导多能干细胞衍生心肌细胞的高通量生理筛选。
Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1717-27. doi: 10.1016/j.bbamcr.2016.03.003. Epub 2016 Mar 4.
6
Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.源自人类多能干细胞的心肌细胞：从实验室的新奇事物到工业生物医学平台。
Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1728-48. doi: 10.1016/j.bbamcr.2015.10.014. Epub 2015 Oct 31.
7
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: The New Working Horse in Cardiovascular Pharmacology?人诱导多能干细胞衍生的心肌细胞：心血管药理学中的新主力？
J Cardiovasc Pharmacol. 2021 Mar 1;77(3):265-266. doi: 10.1097/FJC.0000000000000981.
8
Human Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation.表型筛选中人类诱导多能干细胞来源的心脏祖细胞：一种转化生长因子-β1受体激酶抑制剂可诱导高效的心脏分化。
Stem Cells Transl Med. 2016 Feb;5(2):164-74. doi: 10.5966/sctm.2015-0114. Epub 2015 Dec 18.
9
An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.使用人诱导多能干细胞衍生的心肌细胞的基于阻抗的方法显著改善了体内心脏毒性风险的体外预测。
Toxicol Appl Pharmacol. 2017 Aug 15;329:121-127. doi: 10.1016/j.taap.2017.05.023. Epub 2017 May 22.
10
Induced pluripotent stem-cell-derived cardiomyocytes: cardiac applications, opportunities, and challenges.诱导多能干细胞衍生的心肌细胞：心脏应用、机遇与挑战。
Can J Physiol Pharmacol. 2017 Oct;95(10):1108-1116. doi: 10.1139/cjpp-2016-0726. Epub 2017 Mar 28.
引用本文的文献
1
Effect of iPS cell culture medium on the differentiation potential of induced cardiac tissues.诱导多能干细胞培养基对诱导心脏组织分化潜能的影响。
Sci Rep. 2025 Aug 3;15(1):28301. doi: 10.1038/s41598-025-13259-x.
2
Cardiomyocytes in Hypoxia: Cellular Responses and Implications for Cell-Based Cardiac Regenerative Therapies.缺氧状态下的心肌细胞：细胞反应及其对基于细胞的心脏再生疗法的影响
Bioengineering (Basel). 2025 Feb 6;12(2):154. doi: 10.3390/bioengineering12020154.
3
Advancing Human iPSC-Derived Cardiomyocyte Hypoxia Resistance for Cardiac Regenerative Therapies through a Systematic Assessment of In Vitro Conditioning.通过系统评估体外预处理提高人诱导多能干细胞衍生心肌细胞的缺氧抗性用于心脏再生疗法。
Int J Mol Sci. 2024 Sep 5;25(17):9627. doi: 10.3390/ijms25179627.
4
Characterizing PFAS hazards and risks: a human population-based in vitro cardiotoxicity assessment strategy.描述 PFAS 危害和风险：基于人群的体外心脏毒性评估策略。
Hum Genomics. 2024 Sep 2;18(1):92. doi: 10.1186/s40246-024-00665-x.
5
Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes.利用人多能干细胞衍生的心肌细胞推进心血管药物筛选。
Int J Mol Sci. 2024 Jul 21;25(14):7971. doi: 10.3390/ijms25147971.
6
In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment.从 3D hiPSC 衍生的心脏微组织的体外到体内外推，以及基于生理学的药代动力学建模，为下一代心律失常风险评估提供信息。
Toxicol Sci. 2024 Sep 1;201(1):145-157. doi: 10.1093/toxsci/kfae079.
7
Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.多谱系心脏芯片可模拟药物心脏毒性并促进人干细胞衍生心血管细胞的成熟。
Lab Chip. 2024 Feb 13;24(4):869-881. doi: 10.1039/d3lc00745f.
8
Biotechnological advances and applications of human pluripotent stem cell-derived heart models.人类多能干细胞衍生心脏模型的生物技术进展与应用
Front Bioeng Biotechnol. 2023 Jul 25;11:1214431. doi: 10.3389/fbioe.2023.1214431. eCollection 2023.
9
Automated assessment of human engineered heart tissues using deep learning and template matching for segmentation and tracking.使用深度学习和模板匹配进行分割与跟踪的人源工程心脏组织自动评估。
Bioeng Transl Med. 2023 Apr 18;8(3):e10513. doi: 10.1002/btm2.10513. eCollection 2023 May.
10
Modelling premature cardiac aging with induced pluripotent stem cells from a hutchinson-gilford Progeria Syndrome patient.利用来自一名哈钦森-吉尔福德早衰综合征患者的诱导多能干细胞对心脏早衰进行建模。
Front Physiol. 2022 Nov 23;13:1007418. doi: 10.3389/fphys.2022.1007418. eCollection 2022.
本文引用的文献
1
Direct cardiac reprogramming: from developmental biology to cardiac regeneration.直接心脏重编程：从发育生物学到心脏再生。
Circ Res. 2013 Sep 13;113(7):915-21. doi: 10.1161/CIRCRESAHA.112.300625.
2
Progress in the reprogramming of somatic cells.体细胞重编程的进展。
Circ Res. 2013 Feb 1;112(3):562-74. doi: 10.1161/CIRCRESAHA.111.249235.
3
Immunogenicity of pluripotent stem cells and their derivatives.多能干细胞及其衍生物的免疫原性。
Circ Res. 2013 Feb 1;112(3):549-61. doi: 10.1161/CIRCRESAHA.111.249243.
4
Steps toward safe cell therapy using induced pluripotent stem cells.利用诱导多能干细胞实现安全细胞疗法的步骤。
Circ Res. 2013 Feb 1;112(3):523-33. doi: 10.1161/CIRCRESAHA.111.256149.
5
Functional screening identifies miRNAs inducing cardiac regeneration.功能筛选鉴定出诱导心脏再生的 miRNAs。
Nature. 2012 Dec 20;492(7429):376-81. doi: 10.1038/nature11739. Epub 2012 Dec 5.
6
Whole-genome microRNA screening identifies let-7 and mir-18 as regulators of germ layer formation during early embryogenesis.全基因组 microRNA 筛选鉴定出 let-7 和 mir-18 是早期胚胎发生过程中胚层形成的调节剂。
Genes Dev. 2012 Dec 1;26(23):2567-79. doi: 10.1101/gad.200758.112. Epub 2012 Nov 14.
7
Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.儿茶酚胺多形性室性心动过速的细胞模型显示早期和延迟后除极。
PLoS One. 2012;7(9):e44660. doi: 10.1371/journal.pone.0044660. Epub 2012 Sep 4.
8
High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry.通过动力学图像细胞术对人干细胞衍生心肌细胞中的Ca²⁺动态进行高通量测量以评估药物风险
J Pharmacol Toxicol Methods. 2012 Nov-Dec;66(3):246-56. doi: 10.1016/j.vascn.2012.08.167. Epub 2012 Aug 25.
9
Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells.小分子介导的 TGF-β 型 II 受体降解促进胚胎干细胞的心肌生成。
Cell Stem Cell. 2012 Aug 3;11(2):242-52. doi: 10.1016/j.stem.2012.04.025.
10
Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy.生成患者特异性诱导多能干细胞衍生的心肌细胞作为致心律失常性右心室心肌病的细胞模型。
Eur Heart J. 2013 Apr;34(15):1122-33. doi: 10.1093/eurheartj/ehs226. Epub 2012 Jul 13.
Zotero 插件